The Europe immunoassay analyzers market size is expected to reach USD 2.6 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.0% from 2021 to 2028. The rising prevalence of chronic and infectious diseases and the approval and launch of innovative analyzers are major factors driving the market.
The market is anticipated to exhibit significant growth due to the unprecedented COVID-19 pandemic leading to a shortage of diagnostics and infrastructure. This has created vast opportunities for companies operating in the marketplace to bridge the gap between supply and demand. Amid extensive funding in the healthcare sector, equally from public and private sectors, has led to several research projects pertaining to diagnostics, such as central laboratory tests and point of care tests. These initiatives are aiding in the development of tools, such as immunoassay analyzers. The consumption of immunoassays has increased tremendously during this period of a pandemic propelling the further market growth. The uncertainty over the longevity of the pandemic and the need for analyzers is expected to remain strong in the near future, thereby aiding regional growth.
In addition, increasing approval and launch of innovative and advanced analyzers in the key European countries has significantly boosted the market growth. For instance, in April 2021, Germany-based Siemens Healthineers received the CE Mark for its AtellicaVTLi Patient-Side Immunoassay Analyzer. This analyzer is capable of providing test results in 8 minutes to clinicians by utilizing a patient's blood sample. Furthermore, the entrance of leading players in the European region is further expected to create increased access to advanced products. For instance, in February 2021, SysmexCorporation, a Japan-based immunoassay manufacturer, established its new subsidiary, Sysmex Portugal, S.A., in Portugal. With this initiative, the company expanded its presence in Portugal by intensifying its sales and after-sales support networks.
Request a free sample copy or view report summary: Europe Immunoassay Analyzers Market Report
The EIA analyzers segment held the largest revenue share in the market as this technique is used for detecting specific antigens or antibodies in samples
By end use, the hospitals segment held the largest revenue share in 2020, as hospitals are the primary centers for the diagnosis and treatment of chronic diseases
The clinical laboratories segment is anticipated to grow at a rapid pace over the forecast period owing to the increasing establishment of diagnostic labs in key countries
Germany was the largest market in 2020 due to well-established healthcare infrastructure and high adoption of technologically advanced products
In the U.K., the market is anticipated to exhibit the fastest growth over the forecast period due to the growing prevalence of chronic diseases and the geriatric population
Grand View Research has segmented the Europe immunoassay analyzers market on the basis of analyzers, end use, and region:
Europe Immunoassay Analyzers Outlook (Revenue, USD Million, 2016 - 2028)
Enzyme Immunoassay (EIA) Analyzers
Chemiluminescence Immunoassay (CLIA) Analyzers
Fluorescence Immunoassay (FIA) Analyzers
Radioimmunoassay (RIA) Analyzers
Other Analyzers
Europe Immunoassay Analyzers End-use Outlook (Revenue, USD Million, 2016 - 2028)
Hospitals
Blood Banks
Clinical Laboratories
Pharmaceutical and Biotech Companies
Academic Research Centers
Others
Europe Immunoassay Analyzers Regional Outlook (Revenue, USD Million, 2016 - 2028)
Germany
U.K.
France
Italy
Spain
Russia
Belgium
Switzerland
Netherlands
Poland
Austria
Greece
Sweden
Finland
List of Key Players of Europe Immunoassay Analyzers Market
Siemens Healthineers
bioMérieux SA
Abbott Laboratories
Danaher Corporation (Beckman Coulter)
Quidel Corporation
Ortho Clinical Diagnostics
Sysmex Corporation
Bio-Rad Laboratories, Inc.
Becton, Dickinson and Company
F. Hoffmann-La Roche AG
Thermo Fisher Scientific, Inc.
"The quality of research they have done for us has been excellent..."